Compounds > 2-3-dihydro-1h-imidazo(1-2-b)pyrazole

2-3-dihydro-1h-imidazo(1-2-b)pyrazole and Leukemia-P388

2-3-dihydro-1h-imidazo(1-2-b)pyrazole has been researched along with Leukemia-P388* in 1 studies

Other Studies

1 other study(ies) available for 2-3-dihydro-1h-imidazo(1-2-b)pyrazole and Leukemia-P388

Article	Year
Effect of 2,3-dihydro-1 H-imidazo[1,2-b]pyrazole on the proliferation of mouse leukemic and normal cells in vivo. Cancer research, 1980, Volume: 40, Issue:4 Administration of 2,3-dihydro-1 H-imidazo[1,2-b]pyrazole (IMPY; NSC 51143), 250 to 500 mg/kg, in Day 5 L1210 and P388 (ascites) tumor-bearing mice did not consistently prolong the life span of tumor-bearing animals. Flow cytometry and autoradiographic studies showed that, after 12 to 18 hr of a single IMPY injection, both P388 and L1210 tumor cells were synchronized in S phase. In contrast, IMPY inhibited cellular proliferation in both bone marrow and duodenal crypts during the first 24 hr. and a recovery was detectable only after 36 hr, returning to pretherapy values by 72 hr. Preliminary data indicate that this differential response of normal versus tumor cells to IMPY can be exploited to maximize chemotherapeutic efficacy in scheduled chemotherapy with cycle-specific agents. Topics: Animals; Bone Marrow; Cell Division; DNA, Neoplasm; Duodenum; Imidazoles; Interphase; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Male; Mice; Mice, Inbred Strains; Pyrazoles; Time Factors	1980

Article

Year

Effect of 2,3-dihydro-1 H-imidazo[1,2-b]pyrazole on the proliferation of mouse leukemic and normal cells in vivo.

Cancer research, 1980, Volume: 40, Issue:4

Administration of 2,3-dihydro-1 H-imidazo[1,2-b]pyrazole (IMPY; NSC 51143), 250 to 500 mg/kg, in Day 5 L1210 and P388 (ascites) tumor-bearing mice did not consistently prolong the life span of tumor-bearing animals. Flow cytometry and autoradiographic studies showed that, after 12 to 18 hr of a single IMPY injection, both P388 and L1210 tumor cells were synchronized in S phase. In contrast, IMPY inhibited cellular proliferation in both bone marrow and duodenal crypts during the first 24 hr. and a recovery was detectable only after 36 hr, returning to pretherapy values by 72 hr. Preliminary data indicate that this differential response of normal versus tumor cells to IMPY can be exploited to maximize chemotherapeutic efficacy in scheduled chemotherapy with cycle-specific agents.

Topics: Animals; Bone Marrow; Cell Division; DNA, Neoplasm; Duodenum; Imidazoles; Interphase; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Male; Mice; Mice, Inbred Strains; Pyrazoles; Time Factors

1980